ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 075,68
0,99%
Dow Jones
38 884,26
0,08%
DAX
18 430,05
1,42%
Brent Oil
82,865
-0,73%
Bitcoin
63 031,88
-0,21%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Inozyme Pharma Inc (INZY)

  7. Inozyme Pharma Inc (INZY) Actualités

INZY Inozyme Pharma Inc

4,60
-0,28 (-5,74%)
Après les heures de négociation
Dernière mise à jour : 23:59:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Inozyme Pharma Inc INZY NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,28 -5,74% 4,60 23:59:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,79 4,53 4,84 4,60 4,88
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/5/202414:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202414:32EDGAR2Form 8-K - Current report
07/5/202414:30GLOBEInozyme Pharma Reports First Quarter 2024 Financial Results..
03/5/202414:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
08/4/202412:30GLOBEInozyme Pharma Announces Positive Topline Data from Ongoing..
06/4/202400:00GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
02/4/202414:30GLOBEInozyme Pharma to Participate at the 23rd Annual Needham..
26/3/202413:30GLOBEInozyme Pharma to Report Topline Data from Ongoing Phase 1/2..
12/3/202413:30GLOBEInozyme Pharma Reports Full Year 2023 Financial Results and..
26/2/202414:30GLOBEInozyme Pharma to Participate in the TD Cowen 44th Annual..
14/2/202414:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202403:06EDGAR2Form SC 13D/A - General statement of acquisition of..
06/2/202414:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
05/12/202314:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
16/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
09/11/202314:30GLOBEInozyme Pharma to Participate in Upcoming Investor..
07/11/202322:07EDGAR2Form S-3 - Registration statement under Securities Act of..
07/11/202314:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202314:31EDGAR2Form 8-K - Current report
07/11/202314:30GLOBEInozyme Pharma Reports Third Quarter 2023 Financial Results..
03/11/202321:15GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
26/10/202314:30GLOBEInozyme Pharma Announces Presentation at the American..
10/10/202314:30GLOBEInozyme Pharma Highlights Inclusion of Generalized Arterial..
06/10/202314:30GLOBEInozyme Pharma Announces Three Poster Presentations at the..
03/10/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:12EDGAR2Form 8-K - Current report
26/9/202313:30GLOBEInozyme Pharma Announces Positive Interim Data from Ongoing..
20/9/202314:30GLOBEInozyme Pharma to Host Virtual Investor and Analyst Event on..
06/9/202314:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
05/9/202314:30GLOBEInozyme Pharma to Present at the H.C. Wainwright 25th Annual..
11/8/202322:08EDGAR2Form SC 13D/A - General statement of acquisition of..
08/8/202315:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202314:37EDGAR2Form 8-K - Current report
08/8/202314:30GLOBEInozyme Pharma Reports Second Quarter 2023 Financial Results..
08/8/202303:58EDGAR2Form SC 13D/A - General statement of acquisition of..
04/8/202302:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202322:01GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
01/8/202322:01GLOBEInozyme Pharma, Inc. Announces Closing of Public Offering of..
28/7/202323:19EDGAR2Form 8-K - Current report
28/7/202323:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/7/202305:20GLOBEInozyme Pharma, Inc. Announces Pricing of Public Offering of..
27/7/202323:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/7/202322:33GLOBEInozyme Pharma, Inc. Announces Proposed Offering of Common..
26/7/202313:42EDGAR2Form 8-K - Current report
26/7/202313:30GLOBEInozyme Pharma Announces Updates on Global Development..
19/7/202314:30GLOBEInozyme Pharma to Provide ENPP1 Deficiency Program Update on..
27/6/202314:30GLOBEInozyme Pharma Announces Dosing of First Infant with ENPP1..
02/6/202313:30GLOBEInozyme Pharma to Present at the Jefferies Healthcare..
09/5/202314:30GLOBEInozyme Pharma Reports First Quarter 2023 Financial Results..

Dernières Valeurs Consultées

NASDAQ
INZY
Inozyme Pharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés